Sell Alert: 5 Stocks Analysts Downgraded on Wednesday

Analysts downgraded five stocks on Wednesday, November 11, 2026. Halozyme (HALO) was downgraded by Morgan Stanley to Equal-Weight with a $109 price target. Life360 (LIF) was downgraded by BofA Securities to Neutral with a $45 price target. Akamai (AKAM) was downgraded by Evercore ISI to In-Line with a $90 price target. Riot Platforms (RIOT) was downgraded by Keefe, Bruyette & Woods to Market Perform with a $23 price target.

Original reporting
Published Nov 13, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sell Alert: 5 Stocks Analysts Downgraded on Wednesday — source image
Decision brief

The 30-second read

$HALOBearishMed
01

Why it matters

Downgrades and target cuts provide fresh sell‑side catalysts for the listed companies, potentially driving short‑term price declines.

02

Market read

Analyst rating changes are immediate triggers for trading decisions in the affected stocks.

03

What to watch

Potential upside from upcoming product pipelines or contract wins not reflected in the downgrades.

Relevance 6/10Novelty 6/10Timing: post‑Wednesday (Nov 11) downgrade announcements

Background

The article compiles a list of five stocks that received analyst downgrades on Wednesday, November 11, 2026.

Company-level read

Ticker impact

$HALOBearishHigh confidence
Context

Analyst Morgan Stanley downgraded Halozyme Therapeutics and lowered its price target on November 11.

Expected impact

likely pressure as the market prices in the downgrade

Evidence & confidence

Analyst downgrade is a fresh catalyst that typically triggers sell‑offs for small‑cap biotech.

$LIFBearishHigh confidence
Context

BofA Securities cut Life360 to Neutral and reduced its price target on November 11.

Expected impact

likely pressure as investors digest the lower outlook

Evidence & confidence

Downgrade with a 33% target reduction is a material new piece of information.

$AKAMBearishHigh confidence
Context

Evercore ISI downgraded Akamai Technologies and cut its price target on November 11.

Expected impact

likely pressure as the market reacts to the downgrade

Evidence & confidence

Analyst downgrade is a fresh catalyst for a technology stock.

$RIOTNeutralMedium confidence
Context

Keefe, Bruyette & Woods moved Riot Platforms to Market Perform and raised its price target on November 11.

Expected impact

limited move, possible slight upside from rating upgrade

Evidence & confidence

Rating upgrade may offset target increase; impact expected to be muted.

Market effects

Technology and biotech sectors may see broader sell‑offs as analysts tighten expectations.

U.S. small‑cap and growth stocks could face heightened volatility.

Limited to U.S. equities; no direct global macro effect.

Counterpoint

Some investors may view the downgrades as over‑reaction and look for buying opportunities.

Key entities

  • Morgan Stanley

    Downgraded Halozyme Therapeutics.

  • BofA Securities

    Downgraded Life360.

  • Evercore ISI

    Downgraded Akamai Technologies.

  • Keefe, Bruyette & Woods

    Moved Riot Platforms to Market Perform.

Related articles

$RIOTMedAI 8/10

Bitcoin Miners Lead Wall Street's Crypto Sell-Off: Why Are They Falling Hardest?

Bitcoin fell to $68,000, its lowest since August, dragging down related stocks. Miners like Hut 8 (-6%), Riot Platforms (-3.9%), and MARA Holdings (-3.9%) saw steep declines, while Coinbase slipped 0.5%. The drop follows higher-than-expected US inflation data, increasing bets on a Fed rate hike in December. Miners are hit harder due to income tied to Bitcoin's price. Some miners are diversifying into AI, offering potential relief.

$JPMMed

JPMorgan Chase (JPM) Ramps Up Crypto Investments

JPMorgan Chase (JPM) increased its investments in crypto-related stocks, raising its stake in MicroStrategy (MSTR) by 36% and in BlackRock's iShares Bitcoin Trust (IBIT) by 10%. The bank also holds positions in Coinbase (COIN), Robinhood (HOOD), and several Bitcoin mining companies. JPMorgan's stock has a consensus Moderate Buy rating with an average price target of $378.67.

$MPMed

Wall Street Wrap: Nvidia Faces Downgrades As Jensen Huang’s Exit Rattles Analysts — AMD, MP Materials, Riot Platforms Get Bullish Calls

MP Materials (MP) was upgraded to 'Buy' by Freedom Broker, despite a lowered price target to $51, citing strong Q3 revenue growth and cost-cutting. Riot Platforms (RIOT) was upgraded to 'Buy' by Jefferies, with a raised target to $28, due to favorable lease economics. DraftKings (DKNG) was downgraded by Berenberg and Wells Fargo, with lowered targets and revised outlooks due to heavy investment and regulatory uncertainty.